NM_025137.4:c.6878G>A
Variant summary
Our verdict is Likely benign. The variant received -2 ACMG points: 0P and 2B. BP4_Moderate
The NM_025137.4(SPG11):c.6878G>A(p.Arg2293Gln) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000196 in 1,613,878 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R2293W) has been classified as Likely benign.
Frequency
Consequence
NM_025137.4 missense
Scores
Clinical Significance
Conservation
Publications
- hereditary spastic paraplegia 11Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: ClinGen, Orphanet, Genomics England PanelApp, Labcorp Genetics (formerly Invitae), Illumina, G2P
- amyotrophic lateral sclerosis type 5Inheritance: AR Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae), Genomics England PanelApp
- Charcot-Marie-Tooth disease axonal type 2XInheritance: AR Classification: STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), Orphanet, Genomics England PanelApp
- juvenile amyotrophic lateral sclerosisInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Likely_benign. The variant received -2 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| SPG11 | NM_025137.4 | c.6878G>A | p.Arg2293Gln | missense_variant | Exon 38 of 40 | ENST00000261866.12 | NP_079413.3 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.000158 AC: 24AN: 152088Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.000115 AC: 29AN: 251124 AF XY: 0.0000958 show subpopulations
GnomAD4 exome AF: 0.000200 AC: 293AN: 1461672Hom.: 1 Cov.: 32 AF XY: 0.000198 AC XY: 144AN XY: 727136 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.000158 AC: 24AN: 152206Hom.: 0 Cov.: 32 AF XY: 0.000188 AC XY: 14AN XY: 74402 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
not provided Uncertain:4
- -
SPG11: PM2 -
Reported previously in a patient with Parkinson's disease, however further clinical information was not provided (Ghani et al., 2015); In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 29119460, 25174650) -
Available data are insufficient to determine the clinical significance of the variant at this time. The frequency of this variant in the general population is uninformative in assessment of its pathogenicity. (http://gnomad.broadinstitute.org) Polyphen and MutationTaster yielded discordant predictions regarding whether this amino acid change is damaging to the protein. -
Hereditary spastic paraplegia 11 Uncertain:3
- -
This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 2293 of the SPG11 protein (p.Arg2293Gln). This variant is present in population databases (rs201721414, gnomAD 0.04%). This missense change has been observed in individual(s) with Parkinson's disease (PMID: 25174650). This variant is also known as p.Arg2180Gln. ClinVar contains an entry for this variant (Variation ID: 522343). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Deleterious"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0". The glutamine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
- -
not specified Uncertain:1
Variant summary: SPG11 c.6878G>A (p.Arg2293Gln) results in a conservative amino acid change located in the Spatacsin, C-terminal domain of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00012 in 251124 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in SPG11 causing Hereditary Spastic Paraplegia, Type 11 (0.00012 vs 0.0011), allowing no conclusion about variant significance. c.6878G>A has been reported in the literature in an individual affected with Parkinson's disease (Ghani_2016). This report does not provide unequivocal conclusions about association of the variant with Hereditary Spastic Paraplegia, Type 11. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publication have been ascertained in the context of this evaluation (PMID: 25174650). ClinVar contains an entry for this variant (Variation ID: 522343). Based on the evidence outlined above, the variant was classified as uncertain significance. -
Inborn genetic diseases Uncertain:1
The c.6878G>A (p.R2293Q) alteration is located in exon 38 (coding exon 38) of the SPG11 gene. This alteration results from a G to A substitution at nucleotide position 6878, causing the arginine (R) at amino acid position 2293 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -
Amyotrophic lateral sclerosis type 5 Uncertain:1
- -
Charcot-Marie-Tooth disease axonal type 2X Uncertain:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at